We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
The current 0XOD market cap is 0. The company's latest EPS is USD -3.3125 and P/E is -3.89.
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Total Revenue | 18k | 11.8M | 48.04M | 64.36M | 82.71M |
| Operating Income | -109.48M | -126.74M | -92.29M | -79.04M | -65.54M |
| Net Income | -105.15M | -128.48M | -110.82M | -109.78M | -102.24M |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Total Assets | 202.39M | 122.01M | 119.75M | 135.62M | 178.31M |
| Total Liabilities | 22.09M | 25.65M | 111.33M | 224.98M | 243.52M |
| Total Equity | 180.3M | 96.36M | 8.41M | -89.36M | -65.21M |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Operating | -71.02M | -105.89M | -84.89M | -87.56M | -76.38M |
| Investing | -145.59M | 93.24M | 4.07M | 1.06M | -953k |
| Financing | 165.25M | 16.53M | 72.32M | 97.13M | 116.93M |
| Market Cap | 0 |
| Price to Earnings Ratio | -3.89 |
| Price to Sales Ratio | 4.81 |
| Price to Cash Ratio | 4.18 |
| Price to Book Ratio | -6.1 |
| Dividend Yield | - |
| Shares Outstanding | 30.87M |
| Average Volume (1 week) | 0 |
| Average Volume (1 Month) | 0 |
| 52 Week Change | - |
| 52 Week High | - |
| 52 Week Low | - |
| Spread (Intraday) | 0 (0%) |
| Company Name | Urogen Pharma Ltd |
| Address |
9 hataasiya st ra'anana, center 4365007 |
| Website | https://www.urogen.com |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
